Facebook Pixel Medical Devices Rules, 2017 Opens Up Enormous Opportunities | Bio Spectrum - Business - Bu hikayeyi Magzter.com'da okuyun
Magzter GOLD ile Sınırsız Olun

Magzter GOLD ile Sınırsız Olun

Sadece 9.000'den fazla dergi, gazete ve Premium hikayeye sınırsız erişim elde edin

$149.99
 
$74.99/Yıl

Denemek ALTIN - Özgür

Medical Devices Rules, 2017 Opens Up Enormous Opportunities

Bio Spectrum

|

November 2017

The new Medical Devices Rules, 2017 seek to remove regulatory bottlenecks to make in India, facilitate ease of doing business while ensuring availability of better medical devices for patient care and safety. The rules will also regulate a much larger set of medical devices under a framework customized for medical devices. The stakeholders are hoping that the system will be industry friendly and will indeed create an ecosystem that will enable to boost medical technology innovation and manufacturing in the country.

- Narayan Kulkarni

Medical Devices Rules, 2017 Opens Up Enormous Opportunities

On January 31, 2017 the Ministry of Health and Family Welfare has notified Medical Devices Rules, 2017. The new Rules have been framed in conformity with Global Harmonisation Task Force (GHTF) framework and conform to best international practices. The rules will come in to force with effect from January 1, 2018. Only 15 categories of medical devices are, at present, regulated as drugs and to that extent, the current regulatory practices in India were not fully geared to meet the requirements of medical devices sector in the country.

Medical devices will, under the new Rules, be classified as per GHTF practice, based on associated risks, into Class A (low risk), Class B (low moderate risk), Class C (moderate high risk) and Class D (high risk). The manufacturers of medical devices will be required to meet risk proportionate regulatory requirements that have been specified in the Rules and are based on best international practices.

With a view to bring in the highest degree of professionalism in regulation of medical devices, a system of ‘Third Party Conformity Assessment and Certification’ through Notified Bodies is envisaged. The Notified Bodies will be accredited by the National Accreditation Board for Certification Bodies (NABCB). The NABCB will, before accrediting Notified Bodies, assess their competence in terms of required human resources and other requirements. These Bodies will undertake verification and assessment of Quality Management System of Medical Device Manufacturers of Class A and Class B category and may, on as required basis, be called upon to render assistance for regulation of Class C and D medical devices also.

Bio Spectrum'den DAHA FAZLA HİKAYE

Bio Spectrum

Bio Spectrum

Can India's CDMOS Lead the Next Biopharma Wave?

India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).

time to read

8 mins

March 2026

Bio Spectrum

Bio Spectrum

Telangana turns catalyst for innovation

Telangana is at a pivotal moment in its journey as a global life sciences hub.

time to read

6 mins

March 2026

Bio Spectrum

Bio Spectrum

Is AI the New Weapon in the Fight to End TB?

A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).

time to read

2 mins

March 2026

Bio Spectrum

Bio Spectrum

ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India

US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy

Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"

Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer

Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Haleon ropes in Kedar Lele as President for India Subcontinent

Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Centre revises Startup Recognition Framework to strengthen Startup India Action Plan

The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"

In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.

time to read

5 mins

March 2026

Translate

Share

-
+

Change font size